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Abstract
Protein transduction therapy using poly-arginine peptide can deliver the biologically active
proteins. A previous study showed that 11 poly-arginine fused p53 protein (11R-p53) effectively
penetrated across the plasma membrane and inhibited the proliferation of oral cancer cells. How-
ever, the intracellular half-life of the delivered protein was less than 36 h. Previous studies also
showed that 2-methoxyestradiol (2-ME), an endogenous non-toxic estrogenic metabolite, induces
the stabilization of the wild-type p53 protein in human cancer cells posttranscriptionally. In the
present study, we examined whether 2-ME induced the stabilization of 11R-p53 and had an in-
hibitory effect on the proliferation of oral cancer cells. The application of 2-ME significantly
enhanced the inhibitory effect of 11R-p53 on the proliferation of oral cancer cells. However, 2-
ME had no effect on the intracellular half-life of 11R-p53 in oral cancer cells. Of interest is the
finding that 2-ME suppressed the transcriptional activity of NFkappaB, which has an important
role in tumorigenesis, but did not affect p53 transcriptional activity. These results suggest that
2-ME synergistically enhances the 11R-p53-induced inhibition of the proliferation of oral cancer
cells through the suppression of NFkB transcription.
KEYWORDS: tumor, TAT, poly arginine, gene therapy, protein therapy
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Protein transduction therapy using poly-arginine peptide can deliver the biologically active proteins.
A previous study showed that 11 poly-arginine fused p53 protein (11R-p53) eﬀectively penetrated across the plasma membrane and inhibited the proliferation of oral cancer cells. However, the intracellular half-life of the delivered protein was less than 36 h. Previous studies also showed that 2-methoxyestradiol(2-ME), an endogenous non-toxic estrogenic metabolite, induces the stabiliza-
tion of the wild-type p53 protein in human cancer cells posttranscriptionally. In the present study,
we examined whether 2-ME induced the stabilization of 11R-p53 and had an inhibitory eﬀect on the proliferation of oral cancer cells. The application of 2-ME signiﬁcantly enhanced the inhibitory eﬀect of 11R-p53 on the proliferation of oral cancer cells. However, 2-ME had no eﬀect on the intracellular half-life of 11R-p53 in oral cancer cells. Of interest is the ﬁnding that 2-ME suppressed the transcriptional activity of NFκB, which has an important role in tumorigenesis, but did not aﬀect p53 transcriptional activity. These results suggest that 2-ME synergistically enhances the 11R-p53-induced inhibition of the proliferation of oral cancer cells through the suppression of NFkB transcription.
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T he human immunodeﬁciency virus (HIV) TAT protein transduction system has been shown to transduce biologically active proteins into cells［1-3］.
However, this method has critical disadvantages in terms of its low eﬃciency of transduction and its inﬂuence on neuronal plasticity［4, 5］. To overcome these problems,
a novel transduction system utilizing eleven poly-arginine
(11R)has been developed［4］. 11R is highly eﬃcient in delivering proteins into cells in multiple organs and is non-toxic with respect to neuronal function［4］.
Recent advances in molecular oncology have led to the identiﬁcation of proteins that are quantitatively, qualita-
tively or genetically altered in cancer cells. p53 protein is one of the altered proteins in cancer cells, and is mutated or deleted in more than half of human tumors［6］.
Therefore, tumor suppressor protein therapy with wild-
type p53 protein has been proposed as a possible therapy for malignancies lacking active p53. A previous study showed that 11R-fused p53 protein eﬀectively penetrates across the plasma membrane of oral cancer cells(＞95 cells)and translocates into the nucleus［7］. The protein induces the activity of the p21/WAF1 promoter and inhibits the proliferation of human oral cancer cells, and its eﬀect is equivalent to that of adenovirus-mediated p53
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gene therapy［7］. However, the half-life of 11R-p53 is less than 36 h［7］. Therefore, repeated transduction of 11R-p53 is needed for the inhibition of oral cancer cell proliferation［7］. Although the immunogenicity of the transduced protein has not been determined, repeated administration of protein therapy may initiate an immune response. The development of protein therapy to trans-
duce stable proteins or of methods to stabilize the deliver-
ed proteins is important in order to initiate clinical trials of protein therapy.
2-Methoxyestradiol(2-ME)is a metabolic byproduct of estrogen and an anti-mitotic agent that is present in human urine and blood［8］. 2-ME has been shown to inhibit the growth of various tumor cells through the induction of apoptosis［9, 10］. 2-ME can potently inhibit superoxide dismutase, resulting in enhanced formation of reactive oxygen species and thus toxicity to tumor cells
［11］. Also, 2-ME interferes with NFκB transcriptional activity, which plays an important role in tumorigenesis and which has been shown to be aberrant in many types of cancer cells and primary tumors［12-14］. Moreover,
previous studies have shown that 2-ME induces stabiliza-
tion of the wild-type p53 protein in human cancer cells posttranscriptionally［15, 16］, and that adenoviral-
vector-mediated p53 gene transfer followed by 2-ME treatment causes signiﬁcant growth inhibition in human lung cancer cell lines［15］. These results suggest that 2-ME might induce the stabilization of 11R-p53 in oral cancer cells and enhance the inhibitory eﬀect of 11R-p53 on the proliferation of oral cancer cells.
In the present study, we examined whether 2-ME reduced the degradation of 11R-p53 and enhanced the anti-tumor eﬀect of the protein.
Materials and Methods
 
The oral cell line NOS-1, which was established from a patient with oral squamous cell carcinoma and in which the p53 gene was point-mutated at site 248,was a gift from Drs. N. Oku and T,Komori
(Kobe University, Kobe, Japan). The oral cancer cell line SAS, which contains the wild-type p53 gene, and the HSC-3 and HSC-4 cell lines were provided by the Cell Resource Center for Biomedical Research (Tohoku University, Sendai, Japan). All cell lines were maintained in GIT medium(Wako Pure Chemical Indus-
tries, Osaka, Japan) supplemented with 100 units/ml penicillin and 100 units/ml streptomycin. The cells were
 
cultured in a 37°C incubator with 5  CO?.
Produc-
tion of 11R-p53 was carried out as described previously
［7］. Brieﬂy, full-length human wild-type p53 cDNA was subcloned into p11R-HA vector. The plasmids were then transformed into BL21-DE3 Escherichia coli cells and 11R-p53 proteins were expressed in the cells by induction with 0.2 mM isopropyl-1-thio-βD-galactopyranoside. The 11R-p53 proteins were puriﬁed using a column of Ni-
NTA agarose(Invitrogen, San Diego, CA, USA).
Cell proliferation was assessed as described previously［7］. Brieﬂy, cells were plated in 96-well plates at a density of 4×10?cells/
well in quintuplicate. After 24 h, the cells were incubated with 1μM 11R-p53 with/without 10μM 2-ME(Sigma-
Aldrich Chemical, St. Louis, MO, USA). The cell medium supplemented with 10μM 2-ME was exchanged every 24 h. Control cells received only the vehicle(0.1 DMSO). Cell growth was assessed every 24 h by measuring the conversion of the triazolium salt WST-1
(Roche Applied Science, Mannheim, Germany)to forma-
zan according to the manufacturer’s instructions.
Western blotting analysis for p53 and actin was carried out as described previously［17］. Brieﬂy, the harvested cells were lysed by boiling and sonication containing 1  SDS. Samples containing 50μg of total protein were electrophoresed on 10  SDS-PAGE gels and then transferred to nitrocel-
lulose membranes (Hybond ECL;Amersham Biosci-
ences, Piscataway, NJ, USA). The blots were probed with primary antibodies against human p53(1:1000;Pab 1801;Santa Cruz Biotechnology, Santa Cruz, CA,
USA)and actin(1:5000;AC-40;Sigma-Aldrich Chemi-
cal, St. Louis, MO, USA). The bands were visualized using a commercial ECL detection kit (Amersham Bio-
sciences).
κ
The reporter assays were performed as described previously［7］. For the p53 reporter assay, the luciferase reporter vector pGL2-basic
(Promega, Madison, WI, USA)containing an inserted 2.4-kbp fragment of the human p21/WAF1 promoter was a gift from Drs. T. Akiyama(Tokyo University, Tokyo,
Japan)and K. Yoshikawa (Osaka University, Osaka,
Japan). pNFκB-TA-Luc plasmid (BD Biosciences Clontech, Palo Alto, CA, USA) was used for the NFκB reporter assay. The luciferase reporter vectors were transfected into－70  conﬂuent NOS-1 cells in
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35-mm dishes using Lipofectamine plus(Invitrogen). The cells were then incubated with 1μM 11R-p53 and 10μM 2-ME for 24 h. The cells were harvested, and the lucifer-
ase activities were measured with a luminometer using a reagent kit(Tokyo Ink, Tokyo, Japan). The background luciferase activity was subtracted in all experiments.
Data were analyzed using either the Student’s t-test to compare 2 conditions or ANOVA followed by planned comparisons of multiple conditions, and P＜0.05 was considered to be signiﬁcant.
Results
 
A previous study showed that 1μM 11R-p53 inhibits the proliferation of both SAS and NOS-1 cells, in which wild-type and point-mutated p53 genes are express-
ed, respectively［7］. In the present study, the oral cancer cells were treated with 1μM 11R-p53 on day 0.
After 4 h, the cells were washed and treated with fresh medium in the presence or absence of 10μM 2-ME,
which is an optimal concentration for the inhibition of the proliferation of cancer cells［9-11, 14］. Treatment with 11R-p53 signiﬁcantly suppressed the proliferation of SAS cells (Figs. 1A and C, day 4, control, 1.56±0.1;
11R-p53, 1.24±0.15, n＝5 each, ?P＜0.05) and NOS-1 cells (Figs. 1B and C, day 4, control, 1.68±
0.12;11R-p53, 1.22±0.13, n＝5, ???P＜0.01) as described previously［7］. Co-application of 11R-p53 and 2-ME inhibited the proliferation of the oral cancer cells more markedly than treatment with 11R-p53 alone(Fig.
1A-C, SAS, day 4, 11R-p53＋2-ME, 0.56±0.08,
n＝5,??P＜0.001 vs. 11R-p53;NOS-1, day 4, 11R-
p53＋2-ME, 0.55±0.13, n＝5,??P＜0.001 vs. 11R-
p53). Moreover, the inhibitory eﬀect of treatment with 2-ME on the proliferation was the same as that of 11R-p53 treatment (Fig. 1 C, SAS, day 4, 2-ME,
0.91±0.11, n＝5,P＞0.05 vs. 11R-p53;NOS-1, day 4, 2-ME, 1.18±0.15, n＝5, P＞0.05 vs. 11R-p53).
These results suggest that co-treatment with 11R-p53 and 2-ME causes enhancement of the individual eﬀects of these agents on the proliferation of oral cancer cells.
To investigate the eﬀect of 2-ME on the stabilization of 11R-p53 in NOS-1 cells, the eﬀect of 2-ME on the time-dependent changes in the level of
 
11R-p53 were observed. A high level of 11R-p53 was detected 6 h after exogenous addition of the protein to the cells in the absence of 2-ME (Fig. 2A). The level was decreased after 12 h and the low level was maintained until 72 h after 11R-p53 addition. Co-application of 10μM
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Fig. 1  2-ME induced the inhibitory eﬀect of 11R-p53 on the proliferation of the oral cancer cell lines, SAS(A)and NOS-1(B). 1
μM 11R-p53 with 10μM 2-ME (11R-p53＋2-ME)or without 2-ME
(11R-p53)was added to the cells at day 0. The medium was changed to fresh medium every 24 h, and for 11R-p53＋2-ME, 10μM 2ME was added in the medium. Cell growth was assessed every 24 h by WST assay as described in“Materials and Methods”. C, Comparison of the inhibitory eﬀect of each treatment on cell growth at day 4.
Data are representative of 5 independent experiments. Bars, S.D.
?P＜0.05, ??P＜0.001 and???P＜0.01.
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2-ME with 11R-p53 had no eﬀect on the level of 11R-p53
(Fig. 2A). The level of 11R-p53 was high 6 h after it was added together with 2-ME, but the high level was not maintained 12 h after the addition. The level of 11R-p53 72 h after the addition was not diﬀerent than the level observed in the absence of 2-ME. The eﬀect of high-dose 2-ME(50μM)was also examined, but 50μM 2-ME did not aﬀect the stabilization of 11R-p53(data not shown).
The eﬀect of 2-ME on the expression of endogenous p53 was next examined in various oral cancer cell lines.
HSC-3 cells harbor an insertion mutation between codons 305 and 306. The p53 protein is prematurely terminated and the predicted molecular weight is 42 kDa. In HSC-4 cells, a heterozygous missense mutation corresponding to a CAG (Gln)→ CGG (Arg)transition in codon 248 was seen in the p53 gene. Each cell line was incubated with
 
Fig.2  A, Time course of the degradation of the 11R-p53 proteins and the eﬀect of 2-ME on the degradation in NOS-1 cells. After incubation with 11R-p53 for 4 h, the cells were washed with PBS twice and were then incubated with fresh medium in the presence or absence of 2-ME
(10μM). The medium was replaced with fresh medium with/without 2-ME(10μM)every 24 h. The cells were collected at the indicated time-points, and Western blotting analysis was performed using anti-p53 and anti-actin antibodies. B, Eﬀect of 2-ME on endogenous p53 expression in oral cancer cell lines. Each cell line was incubated with 10μM 2-ME for 48 h. The cells were then collected and Western blotting analysis was performed using anti-p53 and anti-Actin antibodies. The predicted molecular weight of the p53 protein in HSC-3 cells is 42 kDa.
C, Eﬀect of 2-ME(10μM)on p53 reporter activity. Data are representative of５ independent experiments. Data represent means±S.D.
?P＜0.0001.
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11R-p53 for 48 h and was then collected (Fig. 2B).
2-ME did not induce the expression of endogenous p53 in any of the cell lines. These results suggest that 2-ME had no eﬀect on the expression or stabilization of 11R-p53 and p53 in oral cancer cells.
We also examined the eﬀect of 2-ME on the level of transcriptional activity of 11R-p53 in NOS-1 cells(Fig. 2 C). Transduction of 11R-p53 induced the p53 tran-
scriptional activity (23.5±1.7 fold compared with the control, n＝6 each, ?P＜0.0001). The p53 tran-
scriptional activity in the cells incubated with both 11R-
p53 and 2-ME was the same as that in 11R-p53-
transduced cells(11R-p53＋2-ME, 21±3.7 fold, n＝6,
P＞0.05 vs. 11R-p53), indicating that 2-ME had no eﬀect on the 11R-p53 transcriptional activity. Moreover,
the application of 2-ME did not induce endogenous p53 transcriptional activity without 11R-p53 (2-ME, 1.7±
0.9, n＝6, P＞0.05 vs. control).
κ
Previous studies have shown that 2-ME interferes with NFκB transcriptional activity, resulting in the inhibition of the proliferation of cancer cells and the induction of apoptosis of the cells
［12-14］. The eﬀects of 11R-p53 and 2-ME on the level of NFκB transcriptional activity in NOS-1 cells were examined(Fig. 3). A high level of NFκB activity was observed in the intact cells, and 11R-p53 protein trans-
duction had no eﬀect on the level of transcriptional activity
(1.1±0.1, n＝5, P＞0.05 vs. Cont.). In contrast,
co-application of 11R-p53 and 2-ME signiﬁcantly reduced the level of NFκB transcriptional activity(0.23±0.12,
n＝5, ?P＜0.001 vs. Cont.). Application of 2-ME alone also inhibited the level of NFκB activity to the same extent as co-application of 11R-p53 and 2-ME (Fig. 3,
0.21±0.05, n＝5, ?P＜0.001 vs. Cont.). These results suggest that 2-ME inhibits the NFκB tran-
scriptional activity in the oral cancer cells.
Discussion
 
The results of the present study provided the three following important ﬁndings:1)Co-application of 11R-
p53 and 2-ME signiﬁcantly inhibited the proliferation of oral cancer cells compared with the application of 2-ME alone;2) 2-ME had no eﬀect on the stabilization or expression of either 11R-p53 or endogenous p53 protein in oral cancer cells;3)2-ME reduced the NFκB tran-
scriptional activity but had no eﬀect on the p53 tran-
scriptional activity.
Protein transduction therapy using agents such as poly-arginine and TAT peptides is useful for the delivery of biologically active proteins. However, protein trans-
duction therapy has a disadvantage in terms of the short-term expression of the delivered proteins. The present and previous studies show that the intracellular half-life of the delivered 11R-p53 is less than 24 h［7］.
Previous studies have shown that 2-ME induces posttran-
scriptional stabilization of the wild-type p53 protein in human cancer cells［15, 16］, and that adenoviral-vector-
mediated p53 gene transfer followed by 2-ME treatment causes signiﬁcant growth inhibition in human lung cancer cell lines［15］. In the present study, we investigated whether 2-ME enhanced the stabilization and expression of 11R-p53 in oral cancer cells. However, 2-ME had no eﬀect on the stabilization or expression of either 11R-p53 or endogenous p53 protein in oral cancer cells. It is hard to explain the discrepancy between the previous and present studies because the mechanism of 2-ME-
dependent induction of the stabilization of p53 protein is unclear. One possibility is that the origin of the cancer cell lines was diﬀerent. Previous studies have shown the eﬀect of 2-ME on the induction of p53 protein in human lung cancer cell lines and colorectal carcinoma cell lines
［15, 16］. A method to stabilize the transduced 11R-p53 in oral cancer cells needs to be developed. A previous study showed that a p53 mutant in which lysine residues
 
Fig.3  Eﬀect of 11R-p53 and 2-ME on NFκB transcriptional activity in NOS-1 cells. The cells were transfected with pNF B-TA-Luc plasmid. After 24 h, the cells were incubated with 1μM 11R-p53 and/or 10μM 2-ME for 24 h and were then harvested, and the luciferase activities were measured. Data represent means±S.D.
?P＜0.001
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370, 372, 373, 381, 382 and 386 were replaced by arginine residues was resistant to ubiquitin-proteosome-
mediated degradation, and that the transcriptional activity was higher than that of wild-type p53［18］. This result suggests that stable expression of the fusion protein of the p53 mutant with 11R is maintained in oral cancer cells.
Another possible method of stabilization is the transduc-
tion of a phosphorylated form of 11R-p53. Phosphoryla-
tion of p53 at Ser15 and/or Ser20 induces stabilization of p53 by inhibiting of the binding with MDM2, which is critical for ubiquitin-proteosome-mediated degradation
［19］. Direct addition of phospho-11R-p53, which was previously phosphorylated in vitro, may solve the prob-
lem of the stabilization of 11R-p53.
In the present study, the growth of SAS cells with wild-type p53 gene was suppressed by wild-type p53 protein transduction. The expression of p53 is regulated by the action of Mdm2, an oncogenic E3 ligase, to induce p53 ubiquitination and degradation［20, 21］. The human Mdm2 is overexpressed in a wide range of human cancers in which wild-type p53 is expressed, and the overexpres-
sion of Mdm2 serves to inactivate p53 function in these cells［22, 23］. These results may suggest that Mdm2 overexpresses in SAS cells and induces the rapid degrada-
tion of p53. Therefore, 11R-p53 transduction may eﬀectively inhibit the proliferation of the cells.
Interestingly, the present results showed that 2-ME inhibited the NFκB transcriptional activity. Numerous studies have examined the tumor-inhibiting potential of 2-ME［8-11, 14, 24］. Moreover, co-application of adenoviral-vector-mediated p53 gene transfer and 2-ME causes signiﬁcant growth inhibition in human lung cancer cell lines［15］. However, the exact mechanism by which 2-ME inhibits cancer cell proliferation is unknown. A very recent report showed that 2-ME preferentially inhibits the growth of brain tumor cells by blocking cell cycle progression in the G?/M phase and induces apoptosis of the tumor cells［14］. In addition, 2-ME reduces the transcriptional activity and DNA binding activity of NFκB but does not inﬂuence the expression of p53［14］. The present results agree with those results,
and show that 2-ME did not alter p53 expression or a p53 transcriptional activity. NFκB has been suggested to have a wide-ranging role in tumor progression, and its activity is associated with angiogenesis and metastasis
［12, 13］. Also it is known to be required for the transforming properties of many oncogenes, such as Bcr-Abl, Ras and the human T cell lymphotrophic virus
 
1(HTLV 1)protein Tax［25-28］. These results suggest that NFκB activation may be crucial for cancer cell growth and that 2-ME may inhibit cell growth through the inhibition of NFκB activation, not through a p53-
mediated pathway in oral cancer cells.
In contrast, we previously showed that 11R-p53 inhibited the proliferation of oral cancer cells without any signiﬁcant induction of apoptosis［7］. Moreover, 11R-
p53 induces the activity of the promoter of p21/WAF,
which mediates G1 arrest via its inhibitory eﬀects on the cyclin-dependent kinases (CDKs) required for S-phase entry［29, 30］. These results may suggest that 11R-p53 inhibits the growth of oral cancer cells by means of the induction of cell-cycle arrest, and that the mechanism of the growth inhibition induced by 11R-p53 is diﬀerent from that induced by 2-ME. Therefore, co-application of 11R-p53 and 2-ME might cause a signiﬁcant additive inhibitory eﬀect on the proliferation of oral cancer cells compared with the independent application of each agent alone in the present study. 2-ME is a natural metabolic by-product of estrogen and causes no adverse reactions such as hair loss, intestinal damage or infection［31］.
These results suggest that co-application of 11R-p53 and 2-ME has great potential as a chemotherapeutic treatment for oral cancer.
In conclusion, 2-ME had no eﬀect on the stabilization or expression of 11R-p53, but signiﬁcantly inhibited oral cancer proliferation. Our current ﬁndings may be useful for the development of a novel oral cancer therapy.
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